Recent discoveries in genetics and genomics hold great promise for the development of target-defined prevention- and chemotherapeutic-strategies for breast and ovarian cancer. However, a coordinated, multidisciplinary research effort is required to translate these new research discoveries into the next generation of therapeutic strategies. To meet this challenge the Breast and Ovarian Cancer Program aims to 1) define eariy events in breast and ovarian carcinogenesis, 2) translate these advances into targeted therapeutic approaches for the prevention and treatment of breast and ovarian cancer, and 3) test these new therapies in investigator-initiated and multi-institutional clinical trials. The Program includes 29 full and 10 associate members from twelve basic and clinical departments within Duke University. Total funding for program members is $15,171,183, of which $10,468,237 is from peer-reviewed sources. A cancer focus is illustrated by $8,076,169 or 77.1% of funding from the NCI, the American Cancer Society or the Department of Defense. Since its inception, the Program has successfully fostered scientific interabtions between members of the Duke Comprehensive Cancer Institute (DCCI) who have basic, translational, and clinical research interests in breast and ovarian cancer. Within the domain of the Program we developed five subprograms that draw from our translational research strength and ability to translate basic science discoveries to impact the eariy detection and treatment of breast and ovarian cancer: 1) Eariy detection strategies for breast and ovarian cancer;2) Methylation imprinting and epigenetic dysregulation;3) Basic breast and ovarian cancer biology and novel therapeutic targeting;4) Genomics;and 5) Disparities for African American women. The diversity of interest and experimental approaches used by the members of the Breast and Ovarian Program represents an effective environment for fostering cross-fertilization of ideas aimed at understanding breast and ovarian cancer. In addition, the Program supports developmental projects, new faculty awards, and tissue procurement and banking. From 2004-2008, program members published 737 papers in peerreviewed journals that bear directly on breast and/or ovarian cancer (increased 498). Program members are highly collaborative. Of these publications, 46% are the result of inter-programmatic collaborations and 51% due to intra-program collaborations (increased from 6% and 10% respectively in 2003).

Public Health Relevance

Breast arid Ovarian Cancer Program fosters scientific interactions between basic, translational, and clinical scientists to generate novel therapeutic strategies for the prevention, detection, and treatment of breast and ovarian cancer. The multi-disiciplinary collaborations fostered by the program allow investigators to make translational discoveries that could not be made by investigators working in isolation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-40
Application #
8601822
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
40
Fiscal Year
2014
Total Cost
$24,278
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Galaz-Montoya, Monica; Wright, Sara J; Rodriguez, Gustavo J et al. (2017) ?2-Adrenergic receptor activation mobilizes intracellular calcium via a non-canonical cAMP-independent signaling pathway. J Biol Chem 292:9967-9974
Lanier, Megan L; Park, Hyeri; Mukherjee, Paramita et al. (2017) Formal Synthesis of (+)-Laurencin by Gold(I)-Catalyzed Intramolecular Dehydrative Alkoxylation. Chemistry 23:7180-7184
Shi, Qiong; Liu, Hongliang; Han, Peng et al. (2017) Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. J Invest Dermatol 137:1749-1756
Woyach, Jennifer A; Ruppert, Amy S; Guinn, Daphne et al. (2017) BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol 35:1437-1443
Wang, Yanru; Freedman, Jennifer A; Liu, Hongliang et al. (2017) Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. Int J Cancer 141:731-743
Fayanju, Oluwadamilola M; Hall, Carolyn S; Bauldry, Jessica Bowman et al. (2017) Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. Am J Surg 214:666-671
Leu, David; Spasojevic, Ivan; Nguyen, Huy et al. (2017) CNS bioavailability and radiation protection of normal hippocampal neurogenesis by a lipophilic Mn porphyrin-based superoxide dismutase mimic, MnTnBuOE-2-PyP5. Redox Biol 12:864-871
Sauer, Scott J; Tarpley, Michael; Shah, Imran et al. (2017) Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. Carcinogenesis 38:252-260
Pan, Yongchu; Liu, Hongliang; Wang, Yanru et al. (2017) Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Sci Rep 7:44634
Yin, Jieyun; Liu, Hongliang; Liu, Zhensheng et al. (2017) Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus. Mol Carcinog 56:1663-1672

Showing the most recent 10 out of 480 publications